CClinicalTrials.gg
CompletedNCT04933461Updated Jun 21, 2021

Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test C)

An interventional study of Safety lancet in Accident Injury, sponsored by HTL-Strefa S.A.. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-21.

Sponsored by HTL-Strefa S.A. · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A simulated clinical use testing to evaluate the Medlance Plus and myLance sharps injury prevention feature in accordance with the FDA's guidance on medical devices with sharps injury prevention features.

Read the detailed description

This study aims to evaluate the safety of the use of the following safety lancets: Medlance Plus and myLance in the prevention of needle-stick injury (NSI) and to evaluate the user's opinion with regard to the handling characteristics of the medical devices.

The simulated use clinical study involves healthcare professionals (HCPs) who routinely use safety lancets to collect blood samples.

02

Conditions studied

  • Accident Injury

Keywords

  • safety lancet
  • capillary blood sampling
  • accidental needle-stick injury
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • evaluators who routinely use safety lancets to collect capillary blood samples (prevention of the learning curve artifacts)
  • evaluators will be United States (US) residents
  • evaluators can read, write, and speak English
  • evaluators are at least 18 years old
  • evaluators are able to understand and provide signed consent for the study
  • evaluators are willing to comply with the study protocol, including being willing to answer questions and complete questionnaires.
  • evaluators have no concerns about the ability to perform the simulated skin pricking.

Exclusion criteria

Exclusion Criteria:

  • evaluators who do not routinely use safety lancets to collect capillary blood samples,
  • evaluators who cannot read, write, and speak English,
  • evaluators or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or
  • evaluators who have participated in a product evaluation or marketing study involving safety lancets within the last six months
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Other
    Simulation of skin pricking by using Medlance Plus

    Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.

    Device: Safety lancet

  • Other
    Simulation of skin pricking by using myLance

    Estimation of the true failure rate of the device. Estimation of the sharps' injury prevention feature of the tested safety lancets are effective in preventing needle stick injuries.

    Device: Safety lancet

Interventions

  • DeviceSafety lancet

    There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.

05

What researchers measure

Primary outcomes

  1. The true failure rate of the tested devices.

    Time frame: At time of testing, up to 90 minutes

  2. Effectiveness of the safety lancet's sharps injury prevention features.

    Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.

    Time frame: At time of testing, up to 90 minutes

Secondary outcomes

  1. Evaluation of the safety of the devices based on the evaluators' assessments.

    Time frame: At time of testing, up to 90 minutes ]

  2. Evaluation of various aspects of the ease of use.

    Time frame: At time of testing, up to 90 minutes ]

  3. Detection of any handling, usability questions / issues associated with the device.

    Time frame: At time of testing, up to 90 minutes ]

06

Study locations

2 sites
  • Chicago office
    Chicago, Illinois 60606, United States
  • Boston office
    Boston, Massachusetts 02116, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04933461
Lead sponsor
HTL-Strefa S.A.
Responsible party
Sponsor
First posted
Jun 21, 2021
Start date
Sep 24, 2019
Primary completion
Sep 24, 2019
Completion
Sep 27, 2019
Last update
Jun 21, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion